Cancer-fever model travelled to a second hospital—but still needs a treatment trial
A model developed on 987 German hospital stays and tested on 7,409 US stays predicted whether fever would persist after antibiotics, with external AUROC 0.78. Retrospective opportunity counts do not show that withholding escalation is safe.
The short version
- What happened
- The retrospective cohorts contained 987 eligible hospital stays at University Medicine Essen and 7,409 at Brigham and Women's Hospital; persistent fever occurred in 54.0% and 46.5%, respectively.
- Who it affects
- For clinicians, the model could eventually add context during a difficult antibiotic review. For patients with cancer, the priority is proving that fewer escalations or scans do not delay treatment of serious infection.
- What remains unproven
- Retrospective two-centre study of hospital stays; repeat admissions by the same patient may appear more than once.
Keep in mind
Retrospective two-centre study of hospital stays; repeat admissions by the same patient may appear more than once.
Outcome required a recorded temperature 48–72 hours after antibiotics, excluding stays without that measurement.
External calibration shifted with prevalence and care patterns; local recalibration would be required.
No model-guided decision, antimicrobial reduction, diagnostic yield, ICU transfer, mortality or patient-reported outcome was tested.
Public and charitable grants supported authors; the publisher record declares no competing interests.
Source analysis · 1 linked source. Primary analysed source date: 31 October 2026.
Read the full report · 3 min The evidence, methods, implications and limitations
Routine measurements carried a portable signal
A peer-reviewed two-hospital study found that routine data could estimate whether an adult with cancer would remain febrile 48–72 hours after starting intravenous antibiotics. Researchers developed models on 987 eligible hospital stays at University Medicine Essen and externally tested the locked models on 7,409 stays at Brigham and Women's Hospital. Persistent fever occurred in 533 German and 3,442 US stays.
The strongest model, TabPFN, reached an AUROC of 0.82 in nested five-fold internal validation and 0.78 in the external cohort. Its inputs included cancer type, comorbidities, laboratory values, vital signs and temperature patterns. Temperature-related features dominated. The US cohort differed substantially in cancer mix and measurement frequency, making external validation more informative than another split of the same hospital's records.[1]
Prediction is not permission to reduce treatment
Retrospectively, roughly one quarter of antibiotic escalations and chest CT scans occurred among patients the model correctly classified as unlikely to remain febrile. That identifies a possible target for a trial; it does not prove those interventions were unnecessary. A scan may reveal another problem, and antimicrobial decisions in immunocompromised patients depend on more than temperature.
External prevalence fell from 54.0% to 46.5%, and most models underpredicted risk at the US site, indicating that recalibration would be needed. The study excluded admissions without later temperature measurements and counted hospital stays rather than unique people. A prospective study should predefine a safe action, preserve clinician override and measure missed infection, intensive-care transfer, mortality, antimicrobial exposure and imaging—not only model accuracy.[1]
The distinction that matters
What the two-site validation established
The model's discrimination transferred reasonably; treatment safety did not form part of the experiment.
Germany
987 eligible stays; 54.0% persistent fever
Nested-validation AUROC 0.82
United States
7,409 eligible stays; 46.5% persistent fever
Locked-model AUROC 0.78
Next test
Model-guided reassessment
Must measure missed harm and patient outcomes